Zydus Cadila gets a hundred and eighty-day exclusivity for Tofacitinib extended release 22 mg pills by admin- Monday, August 23rd, 2021 04:01:22 PM
Zydus Cadila has received very last approval from the USFDA to marketplace Tofacitinib extendedrelease capsules, 11 mg and 22 mg inside the United States. Zydus become the first ANDA filer on Tofacitinib extended-release tablets 22 mg and presently holds one hundred eighty-day exclusivity in this strength.
Tofacitinib prolonged-launch tablets had annual sales of about $2,082 million in the United States for the year ending June 2021 consistent with IQVIA records. The drug may be manufactured on the institution’s formulation manufacturing facility on the SEZ, Ahmedabad.
The institution now has 321 approvals and has to this point filed over four hundred ANDAs because the graduation of the filing manner in FY 2003-04.